Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Over 2,200 life sciences supply chain professionals gathered in Lyon from 8 – 10th April for LogiPharma 2025, the world’s leading conference dedicated to ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

The decision is the latest blow to Apple’s reputation with artificial intelligence technology and its struggles to market the iPhone 16’s AI features.

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Fintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Eli Lilly and (NYSE:LLY) with a Overweight ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...